TY - JOUR T1 - Projected resurgence of COVID-19 in the United States in July—December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination JF - medRxiv DO - 10.1101/2021.08.28.21262748 SP - 2021.08.28.21262748 AU - Shaun Truelove AU - Claire P. Smith AU - Michelle Qin AU - Luke C. Mullany AU - Rebecca K. Borchering AU - Justin Lessler AU - Katriona Shea AU - Emily Howerton AU - Lucie Contamin AU - John Levander AU - Jessica Salerno AU - Harry Hochheiser AU - Matt Kinsey AU - Kate Tallaksen AU - Shelby Wilson AU - Lauren Shin AU - Kaitlin Rainwater-Lovett AU - Joseph C. Lemaitre AU - Juan Dent AU - Joshua Kaminsky AU - Elizabeth C. Lee AU - Javier Perez-Saez AU - Alison Hill AU - Dean Karlen AU - Matteo Chinazzi AU - Jessica T. Davis AU - Kunpeng Mu AU - Xinyue Xiong AU - Ana Pastore y Piontti AU - Alessandro Vespignani AU - Ajitesh Srivastava AU - Przemyslaw Porebski AU - Srinivasan Venkatramanan AU - Aniruddha Adiga AU - Bryan Lewis AU - Brian Klahn AU - Joseph Outten AU - James Schlitt AU - Patrick Corbett AU - Pyrros Alexander Telionis AU - Lijing Wang AU - Akhil Sai Peddireddy AU - Benjamin Hurt AU - Jiangzhuo Chen AU - Anil Vullikanti AU - Madhav Marathe AU - Stefan Hoops AU - Parantapa Bhattacharya AU - Dustin Machi AU - Shi Chen AU - Rajib Paul AU - Daniel Janies AU - Jean-Claude Thill AU - Marta Galanti AU - Teresa Yamana AU - Sen Pei AU - Jeffrey Shaman AU - Nicholas G. Reich AU - Jessica M. Healy AU - Rachel B. Slayton AU - Matthew Biggerstaff AU - Michael A. Johansson AU - Michael C. Runge AU - Cécile Viboud Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/02/2021.08.28.21262748.abstract N2 - What is already known about this topic?The highly transmissible SARS-CoV-2 Delta variant has begun to cause increases in cases, hospitalizations, and deaths in parts of the United States. With slowed vaccination uptake, this novel variant is expected to increase the risk of pandemic resurgence in the US in July—December 2021.What is added by this report?Data from nine mechanistic models project substantial resurgences of COVID-19 across the US resulting from the more transmissible Delta variant. These resurgences, which have now been observed in most states, were projected to occur across most of the US, coinciding with school and business reopening. Reaching higher vaccine coverage in July—December 2021 reduces the size and duration of the projected resurgence substantially. The expected impact of the outbreak is largely concentrated in a subset of states with lower vaccination coverage.What are the implications for public health practice?Renewed efforts to increase vaccination uptake are critical to limiting transmission and disease, particularly in states with lower current vaccination coverage. Reaching higher vaccination goals in the coming months can potentially avert 1.5 million cases and 21,000 deaths and improve the ability to safely resume social contacts, and educational and business activities. Continued or renewed non-pharmaceutical interventions, including masking, can also help limit transmission, particularly as schools and businesses reopen.Competing Interest StatementJL has served as an expert witness on cases where the likely length of the pandemic was of issue. MCR reports stock ownership in Becton Dickinson & Co., which manufactures medical equipment used in COVID-19 testing, vaccination, and treatment. JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI. there are no other competing interests to declare.Funding StatementKatriona Shea reports receipt of two National Science Foundation (NSF) COVID-19 RAPID awards, and a Huck Institutes of the Life Sciences Coronavirus Research Seed Grant. Rebecca Borchering reports funding from an NSF COVID-19 RAPID award. Katharine Tallaksen, Kaitlin Rainwater-Lovett, Laura Asher, Luke C. Mullany, Molly E. Gallagher, Matt Kinsey, Richard F. Obrecht, and Lauren Shin report funding from the U.S. Department of Health and Human Services (HHS), Office of the Assistant Secretary for Preparedness and Response to the Johns Hopkins Applied Physics Laboratory. Matteo Chinazzi reports grants from the National Institutes of Health (NIH), the Council of State and Territorial Epidemiologists (CSTE), and Metabiota to Northeastern University. Ana Pastore y Piontti reports funding from Metabiota, Inc. to Northeastern University and royalties from Springer Publishing. Joseph Lemaitre reports funding from the Swiss National Science Foundation, State of California, HHS, and the Department of Homeland Security (DHS). Kyra H. Grantz reports support from the California Department of Public Health, Johns Hopkins Bloomberg School of Public Health, NIH, and travel support from the World Health Organization (WHO). Elizabeth Lee and Claire Smith report support from the California Department of Public Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins Health System, HHS, and DHS, and computing resources from Amazon Web Services, Johns Hopkins University Modeling and Policy Hub, and the Office of the Dean at the Johns Hopkins Bloomberg School of Public Health. Justin Lessler reports support from DHHS, DHS, California Institute of Technology, NIH, honorarium from the American Association for Cancer Research, personal fees for expert testimony from Paul, Weiss, Rifkind, Wharton & Garrison, LLP. Lindsay Keegan reports support from the State of California, and NIH, a University of Utah Immunology, Inflammation, and Infectious Disease Seed Grant, and a scholarship from the University of Washington Summer Institute in Statistics and Modeling of Infectious Diseases. Lucie Contamin, John Levander, Jessica Salerno, and Harry Hochheiser report a National Institute of General Medical Sciences grant (U24GM13201). Ajitesh Srivastava reports a grant from the National Science Foundation. Alessandro Vespignani reports grants from NIH, NSF, WHO, CSTE, Metabiota Inc., Templeton Foundation, Scientific Interchange Foundation, Bill & Melinda Gates Foundation; royalties from Cambridge University Press, World Scientific, Springer Publishing, and Il Saggiatore; consulting fees from Human Technopole Foundation, Institute for Scientific Interchange Foundation, honorarium for lecture module at University of Washington; Scientific Advisory Board member of the Institute for Scientific Interchange Foundation, Italy, Supervisory Board member of the Human Technopole Foundation, Italy; and gifts to Northeastern University from the McGovern Foundation, the Chleck Foundation, the Sternberg Family, J. Pallotta, and Google Cloud research credits for COVID-19 from Google. Akhil Sai Peddireddy, Pyrros A. Telionis, Anil Vullikanti, Jiangzhuo Chen, Benjamin Hurt, Brian D. Klahn, Bryan Lewis, James Schlitt, Joseph Outten, Lijing Wang, Madhav Marathe, Patrick Corbett, Przemyslaw Porebski, and Srinivasan Venkatramanan report institutional support from the National Science Foundation, Expeditions, NIH, the U.S. Department of Defense, Virginia Department of Health, Virginia Department of Emergency Management, University of Virginia (internal seed grants), and Accuweather. No other potential conflicts of interest were disclosed.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This analysis was conducted using publicly available, aggregated data on cases and deaths, along with published parameter estimates. No human subjects research was involved, and no IRB approval was required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll projection results are publicly available. Other data referred to in the manuscript are from publicly available sources cited in the manuscript. https://covid19scenariomodelinghub.org/ https://github.com/midas-network/covid19-scenario-modeling-hub ER -